Clinical Trials Logo

Iron Metabolism Disorders clinical trials

View clinical trials related to Iron Metabolism Disorders.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05510440 Not yet recruiting - Clinical trials for Inflammatory Response

Supplementation With Altha-aminoacids and Systemiec Inflammatory Response in Long-distance Runners.

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

It is also noteworthy that the imbalance between the production, supply and elimination of especially α-amino acids may contribute to the intensification of the inflammatory response and the subsequent burden of the renal tubules, which may result in damage and developing chronic renal failure. Among the many amino acids used in sports, arginine and its metabolites deserve special attention. The role of arginine appears to increase in specific physiological states associated with disease, injury or significant strain on the body, leading to an increase in the rate of catabolic transformation. Arginine plays a significant role in protein biosynthesis and detoxification processes related to ammonia removal and urea formation .

NCT ID: NCT02882477 Not yet recruiting - Diabetes Mellitus Clinical Trials

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Start date: December 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Patients who are genetically diagnosed with the recently reported and rare Wolfram syndrome type 2 ( WFS2) and have the degenerative and symptomatic disease including signs such as diabetes, platelet aggregation defect or visual problems will be asked to participate in this study. Knowing the pathomechanism of WFS2 with rapid cell death, after doing baseline investigations to asses the severity of their disease, the participants will be offered a chelator therapy with in addition to the antioxidant Acetylcystein, in diabetic patients an Incertin (GLP-1 ) therapy will be offered as well. The baseline investigations will be repeated after 2 months and after 5 months of therapy in order to asses the progression of the disease and to show if the chelator and anti oxidant therapy and in diabetic patients the GLP-1 therapy could stop the progression of the disease.